Skip to main content
Veterinary Medicines

Aniprantel tabletta A.U.V.

Authorised
  • Praziquantel
  • Pyrantel embonate
  • Fenbendazole

Product identification

Medicine name:
Aniprantel tabletta A.U.V.
Active substance:
  • Praziquantel
  • Pyrantel embonate
  • Fenbendazole
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Praziquantel
    50.00
    milligram(s)
    /
    1.00
    Tablet
  • Pyrantel embonate
    144.00
    milligram(s)
    /
    1.00
    Tablet
  • Fenbendazole
    200.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP52AA51
Authorisation status:
  • Valid
Authorised in:
  • Hungary
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Pharma VIM Kft.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Vim Spectrum S.R.L.
Responsible authority:
  • Directorate Of Veterinary Medicinal Products
Authorisation number:
This information is not available for this product.
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Hungarian (PDF)
Published on: 14/05/2024

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Hungarian (PDF)
Published on: 14/05/2024

Labelling

This document does not exist in this language (English). You can find it in another language below.
Hungarian (PDF)
Published on: 14/05/2024
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."